Presents findings from the 2005 meeting Targeted Therapies in Cancer: Myth or Reality
Reviews the move from empiricism to molecular targeted therapies and its effect on the development of new cancer therapies
Offers readers an overview of diverse approaches, ranging from drug discovery to cellular therapy
Billions of dollars are spent every year on research into targeted therapies for cancer. That´s why it´s more than ever crucial for the thousands of scientists working in the field to keep right up to date with the cutting edge. This fascinating collection of material goes a long way to helping them do so, featuring as it does contributions to a crucial international meeting in Italy. The meeting provided a forum for scientists and clinicians working in cancer drug discovery and therapy to share their opinions and experiences. The text here offers readers an overview of diverse approaches, ranging from drug discovery to cellular therapy. Overall, the book addresses the key question of whether ultimately targeted therapy in cancer will be a myth or a reality.
|
In September 2005 an International Meeting on "Targeted Therapies in Cancer: Myth or Reality" was held in Milan. This successful Meeting was intended to represent a forum for scientists and clinicians working in cancer drug discovery and therapy to share their reflections and experiences on how the paradigm shift from empiricism to molecular targeted therapies is contributing to the translation of basic knowledge into new therapies for cancer patients. This book collects the contributions given by scientists and clinicians, from Academia and Industry, who participated to this Meeting.
We hope that this book contributes to improve our approach to cancer drug discovery and, ultimately, to find new, more efficacious and better tolerated drugs for cancer patients. It provides an overview of diverse approaches ranging from drug discovery to cellular therapy. Although this change in paradigm has been useful, its entry into the clinical arena was associates with unforeseen problems including the emergence of resistance, unexpected side effects and failures. Time is therefore ripe for a critical cultural reflection on the state of the art, prospects and limitations. Ultimately, is targeted therapy in cancer a myth or a reality?
|
Every cancer research scientist will need a copy of this text. As billions of dollars are spent every year on research into targeted therapies for cancer, it´s more than ever crucial for the thousands of scientists working in the field to keep right up to date with the cutting edge. This fascinating collection of material goes a long way to helping them do so, featuring as it does contributions to a crucial international meeting in Italy. The meeting provided a forum for scientists and clinicians working in cancer drug discovery and therapy to share their opinions and experiences on the paradigm shift from empiricism to molecular targeted therapies and its effect on the development of new cancer therapies. The text here offers readers an overview of diverse approaches, ranging from drug discovery to cellular therapy. Overall, the book addresses the key question of whether ultimately targeted therapy in cancer will be a myth or a reality.
Causality in Medicine.- The Evolution of the Biomedical Paradigm in Oncology: Implications for Cancer Therapy.- Anticancer Drug Discovery and Development.- Beyond VEGF: Targeting Tumor Growth and Angiogenesis via Alternative Mechanisms.- Aurora Kinases and Their Inhibitors: More Than One Target and One Drug.- Signalling Pathways and Adhesion Molecules as Targets for Antiangiogenesis Therapy in Tumors.- Developing T-Cell Therapies for Cancer in an Academic Setting.- Anticancer Cell Therapy with TRAIL-Armed CD34+ Progenitor Cells.- Linking Inflammation Reactions to Cancer: Novel Targets for Therapeutic Strategies.- Clinical Development of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: What Lessons Have We Learned?.- GIST As the Model of Paradigm Shift Towards Targeted Therapy of Solid Tumors: Update and Perspective on Trial Design.- Monoclonal Antibodies in the Treatment of Malignant Lymphomas.- Molecular Network Analysis using Reverse Phase Protein Microarrays for Patient Tailored Therapy.
Billions of dollars are spent every year on research into targeted therapies for cancer. The meeting provided a forum for scientists and clinicians working in cancer drug discovery and therapy to share their opinions and experiences. The text here offers readers an overview of diverse approaches, ranging from drug discovery to cellular therapy.
In September 2005 an International Meeting on "Targeted Therapies in Cancer: Myth or Reality" was held in Milan. This successful Meeting was intended to represent a forum for scientists and clinicians working in cancer drug discovery and therapy to share their reflections and experiences on how the paradigm shift from empiricism to molecular targeted therapies is contributing to the translation of basic knowledge into new therapies for cancer patients. This book collects the contributions given by scientists and clinicians, from Academia and Industry, who participated to this Meeting.
We hope that this book contributes to improve our approach to cancer drug discovery and, ultimately, to find new, more efficacious and better tolerated drugs for cancer patients. It provides an overview of diverse approaches ranging from drug discovery to cellular therapy. Although this change in paradigm has been useful, its entry into the clinical arena was associates with unforeseen problems including the emergence of resistance, unexpected side effects and failures. Time is therefore ripe for a critical cultural reflection on the state of the art, prospects and limitations. Ultimately, is targeted therapy in cancer a myth or a reality?
Every cancer research scientist will need a copy of this text. As billions of dollars are spent every year on research into targeted therapies for cancer, it's more than ever crucial for the thousands of scientists working in the field to keep right up to date with the cutting edge. This fascinating collection of material goes a long way to helping them do so, featuring as it does contributions to a crucial international meeting in Italy. The meeting provided a forum for scientists and clinicians working in cancer drug discovery and therapy to share their opinions and experiences on the paradigm shift from empiricism to molecular targeted therapies and its effect on the development of new cancer therapies. The text here offers readers an overview of diverse approaches, ranging from drug discovery to cellular therapy. Overall, the book addresses the key question of whether ultimately targeted therapy in cancer will be a myth or a reality.
Inhaltsverzeichnis
Causality in Medicine.- The Evolution of the Biomedical Paradigm in Oncology: Implications for Cancer Therapy.- Anticancer Drug Discovery and Development.- Beyond VEGF: Targeting Tumor Growth and Angiogenesis via Alternative Mechanisms.- Aurora Kinases and Their Inhibitors: More Than One Target and One Drug.- Signalling Pathways and Adhesion Molecules as Targets for Antiangiogenesis Therapy in Tumors.- Developing T-Cell Therapies for Cancer in an Academic Setting.- Anticancer Cell Therapy with TRAIL-Armed CD34+ Progenitor Cells.- Linking Inflammation Reactions to Cancer: Novel Targets for Therapeutic Strategies.- Clinical Development of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: What Lessons Have We Learned?.- GIST As the Model of Paradigm Shift Towards Targeted Therapy of Solid Tumors: Update and Perspective on Trial Design.- Monoclonal Antibodies in the Treatment of Malignant Lymphomas.- Molecular Network Analysis using Reverse Phase Protein Microarrays for Patient Tailored Therapy.
Klappentext
In September 2005 an International Meeting on ¿Targeted Therapies in Cancer: Myth or Reality¿ was held in Milan. This successful Meeting was intended to represent a forum for scientists and clinicians working in cancer drug discovery and therapy to share their reflections and experiences on how the paradigm shift from empiricism to molecular targeted therapies is contributing to the translation of basic knowledge into new therapies for cancer patients. This book collects the contributions given by scientists and clinicians, from Academia and Industry, who participated to this Meeting.
We hope that this book contributes to improve our approach to cancer drug discovery and, ultimately, to find new, more efficacious and better tolerated drugs for cancer patients. It provides an overview of diverse approaches ranging from drug discovery to cellular therapy. Although this change in paradigm has been useful, its entry into the clinical arena was associates with unforeseen problems including the emergence of resistance, unexpected side effects and failures. Time is therefore ripe for a critical cultural reflection on the state of the art, prospects and limitations. Ultimately, is targeted therapy in cancer a myth or a reality?
Every cancer research scientist will need a copy of this text. As billions of dollars are spent every year on research into targeted therapies for cancer, it's more than ever crucial for the thousands of scientists working in the field to keep right up to date with the cutting edge. This fascinating collection of material goes a long way to helping them do so, featuring as it does contributions to a crucial international meeting in Italy. The meeting provided a forum for scientists and clinicians working in cancer drug discovery and therapy to share their opinions and experiences on the paradigm shift from empiricism to molecular targeted therapies and its effect on the development of new cancer therapies. The text here offers readers an overview of diverse approaches, ranging from drug discovery to cellular therapy. Overall, the book addresses the key question of whether ultimately targeted therapy in cancer will be a myth or a reality.
